Regulations Of The French Market Authority Autorit News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Regulations of the french market authority autorit. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Regulations Of The French Market Authority Autorit Today - Breaking & Trending Today

Strengthening of Pherecydes Pharma's Patent Portfolio with Two New Patents Granted in the United States


(2)
Regulatory News:
Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy for the treatment of resistant and/or complicated bacterial infections, today announced that the United States Patent and Trademark Office (USPTO) has granted two patents for its
anti-Pseudomonas Aeruginosa and
Guy-Charles Fanneau de La Horie, CEO of Pherecydes Pharma, says:
We are very pleased that the USPTO has granted us these two new patents for our anti-Pseudomonas aeruginosa and anti-E. Coli phages. These two new patents in the world s leading healthcare market greatly expand the geographical areas in which our phages are now protected. This is a further evidence of the relevance of the intellectual property strategy we have implemented. We will continue to protect our champion phages with this now proven strategy. ....

United States , Hong Kong , United Kingdom , Pherecydes Pharma , Philippe Rousseau , Nicolas Merigeau , Dusan Oresansky , Prospectus Directive Of The European Union , Trademark Office , Regulations Of The French Market Authority Autorit , European Parliament , Financial Services , Regulatory News , United States Patent , Pseudomonas Aeruginosa , Charles Fanneau De La Horie , French National Agency , French Monetary , Financial Code , General Regulations , French Market Authority , Des March , Prospectus Directive , European Union , Markets Act , Financial Promotion ,

Resounding Success of Pherecydes Pharma's IPO on the Euronext Growth Market in Paris


Resounding Success of Pherecydes Pharma s IPO on the Euronext Growth Market in Paris
Offer oversubscribed 4 times, with global demand totaling €28.1 million
Capital increase of approximately €8 million, after full exercise of the Extension Clause
Trading in the Company s shares begins on February 5, 2021 (FR0011651694 ALPHE)
Regulatory News:
Pherecydes Pharma (Paris:ALPHE) (FR0011651694 ALPHE), a biotechnology company specializing in precision phage therapy to treat resistant and/or complicated bacterial infections, today announces the resounding success of its initial public offering on the Euronext Growth
market in Paris.
Guy-Charles Fanneau de La Horie, Chairman of the Executive Board of Pherecydes Pharma, says:
I am particularly sensitive to the high level of interest the financial community has shown in our IPO project, both institutional and individual investors. I would like to thank all our shareholders, longstanding and new, who h ....

United States , France General , United Kingdom , Pherecydes Pharma , Philippe Rousseau , Bpifrance Entreprise , Kostenloser Wertpapierhandel , Nicolas Merigeau , Dusan Oresansky , Entreprise Innovante , Regulations Of The French Market Authority Autorit , European Parliament , Early Access Program , Financial Services , Company Supervisory Board , Prospectus Directive Of The European Union , Document May Not Be Published , Either Directly , Charles Fanneau De La Horie , Executive Board , Global Placement , Extension Clause , Escherichia Coli , Fixed Price Offer , Euronext Growth , Supervisory Board ,